Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03188965 · ClinicalTrials.gov registry record · Phase 1
First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 229
- Enrollment target
NCT03188965 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 229 participants.
The verdict
NCT03188965, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 229 participants
- Enrollment target
Study Summary
The ATR (ataxia-telangiectasia and Rad3 related protein) inhibitor BAY1895344 is developed for the treatment of patients with advanced solid tumors and lymphomas. The purpose of the proposed trial is to evaluate the safety and tolerability of BAY1895344, and to identify the maximum tolerated dose of BAY1895344 that could be safely given to cancer patients. Further, the response of the cancer to the treatment will be determined.
Interventions
- DRUG Elimusertib (BAY1895344)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2017-07-06 |
| Est. Completion | 2023-09-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03188965
The ClinicalTrials.gov registry entry for NCT03188965 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 229 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Elimusertib (BAY1895344) is the first listed.
NCT03188965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03188965 about?
NCT03188965 is a clinical study titled "First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas". The ATR (ataxia-telangiectasia and Rad3 related protein) inhibitor BAY1895344 is developed for the treatment of patients with advanced solid tumors and lymphomas. The purpose of the proposed trial is to evaluate the safety and tolerability of BAY1895344, and to identify the maximum tolerated dose of...
What is the current status of trial NCT03188965?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 229 participants. The study started on 2017-07-06. Estimated completion is 2023-09-13.
What interventions are being tested in trial NCT03188965?
The interventions under investigation include: Elimusertib (BAY1895344) (DRUG).
Who is sponsoring clinical trial NCT03188965?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.